CurrentAnthemPolicy LAB.00036

Multiplex Autoantigen Microarray Testing for Systemic Lupus Erythematosus

Defines the medical policy stance on multiplex autoantigen microarray tests (eg, Avise® Lupus, Avise CTD, Avise SLE Monitor, SLE-key®) for screening, diagnosis, or management of systemic lupus erythematosus.

Policy Summary

PayerAnthem

PolicyMultiplex Autoantigen Microarray Testing for Systemic Lupus Erythematosus

Policy CodePolicy LAB.00036

Change TypeReviewed — rationale and references updated

Effective DateOct 1, 2025

Next Review Date

Key ActionDo not consider multiplex autoantigen microarray tests for SLE medically necessary; documentation supporting medical necessity will not meet coverage per this policy.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

InvestigationalMultiplex autoantigen microarray testing stance

Avise® LupusManufacturer / test example

0062U, 0312UProprietary test CPT codes referenced

Policy Position and Criteria

Position Statement

Multiplex autoantigen microarray testing to screen for, diagnose, or manage systemic lupus erythematosus is considered investigational and not medically necessary.

Relevant CPT and Diagnosis Codes

Proprietary multiplex autoantigen microarray test codes (Investigational and Not Medically Necessary)CPTNot Covered

0062U	Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score (SLE-key® Rule Out, Veracis Inc.)
0312U	Autoimmune diseases (eg, systemic lupus erythematosus [SLE]), analysis of 8 IgG autoantibodies and 2 cell-bound complement activation products using ELISA, flow cytometry and indirect immunofluorescence, serum or plasma and whole blood, individual components reported along with an algorithmic SLE-likelihood assessment (Avise® Lupus, Exagen Inc.)

Diagnosis codes (informational)ICD-10

All diagnoses

Policy applies to testing ordered for any diagnosis when used to screen, diagnose, or manage SLE (document lists 'All diagnoses' for applicability of coding section).

What Providers Must Do

Documentation Required

Do not treat multiplex array testing as standard diagnostic/management tool

Multiplex autoantigen microarray tests for SLE (including Avise® Lupus and SLE-key®/SLE-key® Rule Out) are considered investigational and not medically necessary; documentation supporting medical necessity for these tests will not satisfy coverage under this policy.

0062U
0312U

Prior Authorization

Commercial HMO — California investigational process

For Commercial HMO members in California, PMGs must not approve or deny requests locally when the medical policy states a procedure is investigational; instead, fax the request to Anthem Blue Cross Grievance and Appeals at the listed fax numbers and contact G&A if needed.

Clinical and Evidence Context

Multiplex autoantigen microarray tests detect large numbers of autoantibodies associated with systemic lupus erythematosus (SLE) using microarray or multianalyte platforms and may combine results with a proprietary algorithm to produce a risk or likelihood score. Examples discussed in the literature and policy include the Exagen Avise® Lupus family of tests (Avise® Lupus, Avise CTD, Avise SLE Monitor) and the SLE-key® test (ImmunArray / SLE-key® Rule Out), with Avise® Lupus using a two-tier approach that incorporates cell-bound complement activation products such as BC4d and EC4d alongside autoantibody markers in an algorithmic assessment of SLE likelihood. (See product descriptions and testing approach in the Background/Overview.)

Clinical studies have shown that these multiplex panels can affect physician diagnostic confidence and management decisions: Putterman et al. (2014) reported diagnostic accuracy for an Avise-like two-tiered analysis with a sensitivity of about 80% and specificity of about 86%; Wallace et al. (2019) conducted a randomized controlled trial in patients referred to rheumatologists and found a greater reduction in physician-reported likelihood of SLE and higher treatment initiation (eg, prednisone) in the Avise testing arm; Alexander et al. (2021) and Ramsey-Goldman et al. (2021) reported observational evidence that positive multianalyte assay panel (MAP) results were associated with higher clinician confidence and prediction of transition from probable to classified SLE; and the CAPSTONE registry analysis (O’Malley et al., 2022) found higher rates of SLE medication initiation among individuals with positive AVISE tests versus standard ANA testing.

Despite these findings, important limitations temper the evidence base: the Avise tests are laboratory-developed and have no FDA labeled indications; many studies are retrospective or nonrandomized, some lacked a gold-standard diagnostic reference at the time of outcome assessment, and randomized data did not report clinical health outcomes. Major clinical practice guidelines do not currently address multiplex autoantigen microarray testing and the American College of Rheumatology has advised selecting specific ANA subserologies based on clinical presentation rather than ordering broad panels. Taken together, these factors have led to the policy position that multiplex autoantigen microarray testing to screen for, diagnose, or manage SLE is considered investigational and not medically necessary.

Policy Summary

PayerAnthem

PolicyMultiplex Autoantigen Microarray Testing for Systemic Lupus Erythematosus

Policy CodePolicy LAB.00036

Change TypeReviewed — rationale and references updated

Effective DateOct 1, 2025

Next Review Date

Key ActionDo not consider multiplex autoantigen microarray tests for SLE medically necessary; documentation supporting medical necessity will not meet coverage per this policy.

SourceLink

On This Page

OpenPayer

Multiplex Autoantigen Microarray Testing for Systemic Lupus Erythematosus

Policy Position and Criteria

Relevant CPT and Diagnosis Codes

What Providers Must Do

Clinical and Evidence Context

Key Definitions

Policy Dates

Multiplex Autoantigen Microarray Testing for Systemic Lupus Erythematosus

Policy Position and Criteria

Relevant CPT and Diagnosis Codes

What Providers Must Do

Clinical and Evidence Context

Key Definitions

Policy Dates

Other Policies to Review